Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis ; volume:36 ; number:1 ; day:6 ; month:5 ; year:2024 ; pages:1-12 ; date:12.2024
Journal of the Egyptian National Cancer Institute / Egyptian National Cancer Institute; 36, Heft 1 (6.5.2024), 1-12, 12.2024
- Creator
-
Rangwala, Hussain Sohail
Fatima, Hareer
Ali, Mirha
Sunder, Sailesh
Devi, Sonia
Rangwala, Burhanuddin Sohail
Abbas, Syed Raza
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s43046-024-00218-2
- URN
-
urn:nbn:de:101:1-2405230715488.901575594135
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rangwala, Hussain Sohail
- Fatima, Hareer
- Ali, Mirha
- Sunder, Sailesh
- Devi, Sonia
- Rangwala, Burhanuddin Sohail
- Abbas, Syed Raza
- SpringerLink (Online service)
Other Objects (12)
Severe Gastritis after Administration of Nivolumab and Ipilimumab
Retinal toxicity after initial administration of nivolumab and ipilimumab
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Correction to: Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report
Severe Gastritis after Administration of Nivolumab and Ipilimumab
Retinal toxicity after initial administration of nivolumab and ipilimumab
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Correction to: Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report
Severe Gastritis after Administration of Nivolumab and Ipilimumab
Retinal toxicity after initial administration of nivolumab and ipilimumab
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Correction to: Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis